Storia in 2 fonti

J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win

Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker

Raccontata da

fiercepharma.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

fiercepharma.comStai leggendo13 h fa

J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win

Questo articolo riguarda un trial farmaceutico (J&J / Imaavy per malattia autoimmune rara) ed è completamente fuori scope per **Warptech Tech News**, che copre AI, tech, business e startup per manager IT/CTO italiani. Non è un pezzo che pubblicheremmo. Se hai articoli tech da riassumere, sono pronto.

originale

benzinga.com11 h fa

Johnson & Johnson Hits Goal With IMAAVY In Rare Blood Disorder - Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson reports Phase 2/3 data showing IMAAVY improved hemoglobin levels in wAIHA patients and secured FDA Priority Review.

Leggi questa versione → originale

Timeline cronologica

giovedì 11 giugno 2026·fiercepharma.com
J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win
Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker
giovedì 11 giugno 2026·benzinga.com
Johnson & Johnson Hits Goal With IMAAVY In Rare Blood Disorder - Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson reports Phase 2/3 data showing IMAAVY improved hemoglobin levels in wAIHA patients and secured FDA Priority Review.